# Gerald W. Prager

Source: https://onco.cc/people/gerald-prager/  
OnCo record `gerald-prager` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Vienna oncologist who was lead author of SUNLIGHT, the trial that showed adding bevacizumab to trifluridine-tipiracil lengthens survival in refractory colorectal cancer.

## Summary

Gerald Prager is a gastrointestinal medical oncologist at the Medical University of Vienna and chairs ESMO's gastrointestinal cancer faculty. He was first author of the 2023 New England Journal of Medicine report of SUNLIGHT, the phase 3 trial in which trifluridine-tipiracil plus bevacizumab improved overall survival compared with trifluridine-tipiracil alone in refractory metastatic colorectal cancer, establishing the combination as a third-line standard.

## Fields

- Kind: Person
- Last checked: 2026-09-18
- Tags: colorectal; trialist
- Role: Gastrointestinal medical oncologist, Medical University of Vienna
- Specialisms: Colorectal cancer; Anti-angiogenic therapy; Later-line chemotherapy

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [KRAS G12C-mutant colorectal cancer](https://onco.cc/cancers/kras-g12c-colorectal/)
- institutions: [Comprehensive Cancer Center Vienna, Medical University of Vienna / AKH](https://onco.cc/institutions/ccc-vienna/)
- key papers: [SUNLIGHT: trifluridine-tipiracil plus bevacizumab in refractory metastatic colorectal cancer](https://onco.cc/key-papers/paper-sunlight-nejm-2023/)

---
JSON: https://onco.cc/api/v1/entities/gerald-prager.json